The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake

被引：0
|
作者：
Flint, Anne
Kapitza, Christoph
Hinds-Berger, Charlotte
Zdravkovic, Milan
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [31] The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
    Lykkegaard, Kirsten
    Larsen, Philip J.
    Vrang, Niels
    Bock, Camilla
    Bock, Troels
    Knudsen, Lotte Bjerre
    SCHIZOPHRENIA RESEARCH, 2008, 103 (1-3) : 94 - 103
  • [32] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    A Astrup
    R Carraro
    N Finer
    A Harper
    M Kunesova
    M E J Lean
    L Niskanen
    M F Rasmussen
    A Rissanen
    S Rössner
    M J Savolainen
    L Van Gaal
    International Journal of Obesity, 2012, 36 : 843 - 854
  • [33] The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
    Anne Flint
    Christoph Kapitza
    Charlotte Hindsberger
    Milan Zdravkovic
    Advances in Therapy, 2011, 28 : 213 - 226
  • [34] The Once-Daily Human Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Improves Postprandial Glucose Levels in Type 2 Diabetes Patients
    Flint, Anne
    Kapitza, Christoph
    Hindsberger, Charlotte
    Zdravkovic, Milan
    ADVANCES IN THERAPY, 2011, 28 (03) : 213 - 226
  • [35] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    Aimaretti, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (08) : 701 - 703
  • [36] Liraglutide: A once-daily human glucagon-like peptide-1 analogue
    G. Aimaretti
    Journal of Endocrinological Investigation, 2009, 32 : 701 - 703
  • [37] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Roessner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 890 - 890
  • [38] Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with glimepiride: all as monotherapy in type 2 diabetes
    Garber, A.
    Henry, R.
    Ratner, R.
    Garcia-Hernandez, P.
    Pattzi, H. M. Rodriguez
    Olvera-Alvarez, I.
    Hale, P. M.
    Zdravkovic, M.
    Bode, B.
    DIABETOLOGIA, 2008, 51 : S358 - S359
  • [39] Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial
    Finer, N.
    Al Hakim, M.
    Astrup, A.
    Harper, A.
    Lean, M.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Van Gaal, L.
    DIABETOLOGIA, 2009, 52 : S11 - S12
  • [40] In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss
    Fonseca, V. A.
    Henry, R. R.
    Tabanera y Palacios, R.
    Brett, J.
    Plutzky, J.
    DIABETOLOGIA, 2010, 53
12345